Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients
Objectives Proliferative capacity of acute myelogenous leukaemia (AML) blasts is important for leukaemogenesis, and we have investigated whether proliferative capacity of primary human AML cells could be used for subclassification of patients. Materials and methods In vitro proliferative capacity of...
Saved in:
Published in | Cell proliferation Vol. 46; no. 5; pp. 554 - 562 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.10.2013
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objectives
Proliferative capacity of acute myelogenous leukaemia (AML) blasts is important for leukaemogenesis, and we have investigated whether proliferative capacity of primary human AML cells could be used for subclassification of patients.
Materials and methods
In vitro proliferative capacity of AML cells derived from two independent groups was investigated. Cells were cultured under highly standardized conditions and proliferation assayed by 3H‐thymidine incorporation after seven days culture. Patients were subclassified by clustering models, and gene expression profile was examined by microarray analyses.
Results
Based on proliferative capacity of the AML cells, three different patient clusters were identified: (i) autocrine proliferation that was increased by exogenous cytokines; (ii) detectable proliferation only in presence of exogenous cytokines; and (iii) low or undetectable proliferation even in presence of exogenous cytokines. Patients with highest proliferative capacity cells had no favourable prognostic impact by NPM‐1 mutation. Analysis of gene expression profiles showed that the most proliferative cells generally had altered expression of genes involved in regulation of transcription/RNA functions, whereas patients with high proliferative capacity and internal tandem duplications (ITDs) in the FLT3 cytokine receptor gene had altered expression of several molecules involved in cytoplasmic signal transduction.
Conclusions
In vitro proliferative capacity of primary human AML cells was considerably variable between patients and could be used to identify biologically distinct patient subsets. |
---|---|
Bibliography: | istex:EB58C8E3F8508F87D0E21945107EEF77D819277A ark:/67375/WNG-BVWDLS0V-R Table S1. List of genes that are differentially expressed (p<0.005) when comparing patients with high and low proliferative capacity (Group I patient cohort).Table S2. List of genes that are differentially expressed (p<0.05) when comparing patients with high and low proliferative capacity (Group I patient cohort) and each of these genes belonging to at least one of the G0-annotation listed in Table 3. ArticleID:CPR12057 |
ISSN: | 0960-7722 1365-2184 |
DOI: | 10.1111/cpr.12057 |